STOCK TITAN
  1. Home
  2. News
  3. KNSA

Kiniksa Pharmaceuticals, Ltd. - $KNSA STOCK NEWS

Welcome to our dedicated page for Kiniksa Pharmaceuticals, Ltd. news (Ticker: $KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals, Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kiniksa Pharmaceuticals, Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kiniksa Pharmaceuticals, Ltd.'s position in the market.

News
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
Rhea-AI Summary

Kiniksa Pharmaceuticals, (Nasdaq: KNSA) will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on May 14, 2024. The presentation will be available via webcast on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
Rhea-AI Summary
Kiniksa Pharmaceuticals reported strong financial results for the first quarter of 2024, with ARCALYST net product revenue reaching $78.9 million, representing an 85% year-over-year growth. The company expects ARCALYST 2024 net product revenue to increase to $370 - $390 million. Additionally, Kiniksa plans to initiate a Phase 2b trial for Abiprubart in Sjögren’s Disease in the second half of 2024. The company's current operating plan is expected to remain cash flow positive. Total revenue for the first quarter of 2024 was $79.9 million, with total operating expenses at $96.4 million. Kiniksa's net loss for the quarter was $17.7 million. The company had $213.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Kiniksa expects 2024 ARCALYST net product revenue to be between $370 - $390 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
earnings
-
News
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
Rhea-AI Summary
Kiniksa Pharmaceuticals, (Nasdaq: KNSA) will report its first quarter 2024 financial results on April 23, 2024. The company will host a conference call and live webcast to discuss recent portfolio execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
conferences earnings
News
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
Rhea-AI Summary
Kiniksa Pharmaceuticals, announces plans to initiate Phase 2b trial in Sjogren’s Disease and presents positive data from Phase 2 Cohort 4 in rheumatoid arthritis with abiprubart. The company expects to remain cash flow positive and fully fund abiprubart development through Phase 3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
News
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. reported strong financial results for Q4 2023 and full-year 2023 with net product revenue of $71.2 million and $233.2 million, respectively. They expect ARCALYST 2024 revenue to reach $360 - $380 million, representing a 59% YoY growth. The company's cash reserves of $206.4 million are expected to fund operations until at least 2027. Positive Phase 2 data for abiprubart in rheumatoid arthritis and plans for a new indication in April 2024 were highlighted. Kiniksa also recognized positive clinical trial results for mavrilimumab and a development milestone for vixarelimab. Financially, total revenue increased to $270.3 million in 2023, with net income of $14.1 million for the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
earnings
-
News
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call and live webcast on February 28, 2024, to report its Q4 and full-year 2023 financial results and recent portfolio execution. Interested individuals can access the webcast through the company's website or participate via telephone by registering. A replay will be available on Kiniksa's website post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences earnings
News
Kiniksa Pharmaceuticals Provides Corporate Update
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported a 90% year-over-year growth in ARCALYST net product revenue to $233.1 million in 2023. They expect ARCALYST 2024 net product revenue to be between $360 - $380 million. Abiprubart (KPL-404) Phase 2 rheumatoid arthritis trial met the primary efficacy endpoint in Cohort 3 at the weekly dose level. Cash reserves of $206.3 million are expected to fund operations into at least 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
none
-
News
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
conferences
-
News
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
Rhea-AI Summary
Kiniksa Pharmaceuticals reports Q3 2023 net product revenue of $64.8 million, a 94% YoY growth. KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024. Cash reserves of $201 million expected to fund operations into at least 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
earnings
News
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
Rhea-AI Summary
Kiniksa Pharmaceuticals to report Q3 2023 financial results and recent portfolio execution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences earnings
Stock KNSA logo
Kiniksa Pharmaceuticals, Ltd.

Nasdaq:KNSA

KNSA Rankings

#2174 Ranked by Market Cap
#604 Ranked by Stock Gains
N/A Ranked by Dividends

KNSA Stock Data

1.44B
31.61M
3.96%
90.25%
4.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
HAMILTON

About KNSA

kiniksa pharmaceuticals combines an experienced management team and significant committed capital in order to acquire, develop, and commercialize therapeutics treating devastating diseases with high unmet needs.